Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Billings Joins Trovagene's SAB

Premium

Trovagene this week said that Paul Billings has joined the company's scientific advisory board.

Billings is a board-certified internist and clinical geneticist, and currently serves as CMO at Life Technologies. He has authored nearly 200 publications and books on genomic medicine and currently serves on the SAB of the US Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. Prior to joining Life Tech, he served as director and CSO of the Genomic Medicine Institute at El Camino Hospital. Previously, he was senior vice president for corporate development at LabCorp. Billings has founded or served as CEO of a number of genetic and diagnostic medicine companies, including GeneSage, Omicia, and Cellective Dx.

Billings has also held academic appointments at Harvard Medical School, Stanford School of Medicine, and the University of California, Berkeley, and has served as a physician at a number of medical centers throughout the country, including the University of California, San Francisco. Billings holds an MD from Harvard Medical School and a PhD in immunology from Harvard University.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.